Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
about
Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) miceAcute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion.Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture.Unrelated umbilical cord blood transplantation and immune reconstitution.Double umbilical cord blood transplant: more than a cell dose?Expansion, purification, and functional assessment of human peripheral blood NK cells.Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients.Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.Expression of CD94 by -differentiated NK cells correlates with the and acquisition of cytotoxic featuresT cell depletion utilizing CD34+ stem cell selection and CD3+ addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients
P2860
Q27318729-8B6E7662-C9B0-4504-B987-ABF74CEE0C27Q34634251-FEE5B04F-3A01-4806-8245-4CAF2BAFDA6BQ35285087-997D8460-3869-4DE0-B586-DFDCFBEA703EQ36407384-F3693BBF-4626-4D1A-9C95-4E38C0084633Q36429009-2A06AFC1-61C2-435A-AC01-FB53B12A2458Q36934304-33741D60-BE01-4BFE-9647-7F7C35D84963Q37724186-03CDE9A4-14DB-44AA-AA02-8CE22B288306Q38568681-C48845F3-E868-4FB3-AB78-169DA45F98BBQ38586429-1A2660A0-C788-4DAF-B60D-B64C299707F5Q38803361-A142A602-6AE7-40AC-9260-BEAAD3C832B4Q47951320-E3DFBC52-6D3F-4D7D-BA9B-49E1ECD58B9CQ48156058-DD0C2CEB-DEDE-4784-ABD3-7EC05560E646Q58125336-3A442752-4B4C-43E6-AF3C-CC7033FB024BQ58449860-3A4B432F-9172-4440-8877-3891A91D9A82
P2860
Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Characterization of cord blood ...... ex vivo cellular engineering.
@en
Characterization of cord blood ...... ex vivo cellular engineering.
@nl
type
label
Characterization of cord blood ...... ex vivo cellular engineering.
@en
Characterization of cord blood ...... ex vivo cellular engineering.
@nl
prefLabel
Characterization of cord blood ...... ex vivo cellular engineering.
@en
Characterization of cord blood ...... ex vivo cellular engineering.
@nl
P2093
P1476
Characterization of cord blood ...... ex vivo cellular engineering.
@en
P2093
Carmella van de Ven
Cheryl Wade-Harris
Diana Pickering
Janet Ayello
Joanne Kurtzberg
Laxmi Baxi
Lynn L Simpson
Mitchell S Cairo
Prakash Satwani
Warren Sanger
P304
P356
10.1016/J.BBMT.2006.01.009
P577
2006-06-01T00:00:00Z